Malignant Gliomas Biorepository Core

恶性胶质瘤生物样本库核心

• 批准号: 8450344
• 负责人: Ichiro Nakano
• 金额: $ 14.87万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8450344
• 关键词: Affect; Biological Assay; Biological Models; Cell Line; Characteristics; Cultured Tumor Cells; Development; Disease; Ensure; Genetic; Genetic Transformation; Glioblastoma; Grant; Instruction; Malignant Glioma; Oncolytic; Operative Surgical Procedures; Patients; Sampling; Serum; Services; Specimen; Therapeutic; Tumorigenicity; base; biobank; in vivo; neoplastic cell; research study; tumor

A reliable model system that is relevant to the disease in question is a critical asset to achieve development of safe and effective therapeutics. It is in particular relevant for glioblastoma, since this tumor is composed of heterogeneous multiple types of tumor cells in patients. Recent studies identified that application of the spheroid cultures enables us to maintain the original phenotypic and genetic characteristics of the parental tumors. Core C will utilize its current services to collect additional glioblastoma spheroids (GSs) from affected patients and uncover the phenotypic and genotypic characteristics of these GSs are particularly relevant to each project as detailed in aim 2. Specifically, we will establish spheroid cultures from surgical specimens and perform in vivo tumorigenicity assay to determine if our samples are able to recapitulate patients' tumors histopathologically. We also would plan to provide these services on an ongoing basis for all five years of the grant since characterized GSs transferred to each project may require re-characterization. As such, this Core will provide services essential to all 4 projects. Significance of this Core as a central biorepository will eliminate variability amongst the projects, ensuring that all projects utilize the same GSs for the proposed experiments.

与有关疾病相关的可靠模型系统是实现发展的关键资产 安全有效的治疗学。它特别与胶质母细胞瘤相关，因为该肿瘤由 患者中多种类型的肿瘤细胞。最近的研究表明，应用 球体培养物使我们能够维持父母的原始表型和遗传特征 肿瘤。 Core C将利用其当前服务从中收集其他胶质母细胞瘤球体（GSS） 受影响的患者并揭示了这些GSS的表型和基因型特征尤其是 与AIM 2中详细介绍的每个项目相关。具体来说，我们将建立手术中的球体文化 标本并执行体内肿瘤性测定法，以确定我们的样品是否能够概括 患者的肿瘤在组织病理学上。我们还计划不断提供这些服务 自从转移到每个项目的GSS的特征以来，赠款的五年可能需要重新特征。 因此，该核心将为所有4个项目提供必不可少的服务。该核心作为中心的意义 BiorePository将消除项目之间的可变性，以确保所有项目都使用相同的GSS 提出的实验。